Mr. Shen has 19 years of industry experience in start-ups and established biotech, pharmaceutical and medical device sectors with expertise across multiple functional settings including R&D, commercial, regulatory, supply chain, finance and information technology. I have consulting experience. His recent focus is on oncology indications. She specializes in clinical asset and company valuation, growth strategy, project and portfolio management, global and US product launch planning, primary and secondary market research, competitive and scenario analysis, sales forecasting and financial modeling. Most recently, she served as Head of Corporate Strategy and Operations at Luzsana, a wholly owned subsidiary of Jiangsu Hengrui Pharmaceuticals, China’s largest pharmaceutical company, reporting to the CEO and overseeing the selection and globalization of pharmaceutical assets. I was responsible for leading.
CEO Scott Filosi said: Having worked with Yi in the past, her experience and leadership will help support our mission to provide potentially life-extending immunotherapeutic drugs to patients suffering from advanced metastatic cancer. From an accelerated, research-focused biotech company to a commercial-focused company. “
Yi Shen said: The founder and his talented team have spent the past 18 years overcoming countless obstacles and resiliently building the platform technology and his GMP manufacturing infrastructure from concept to Phase II clinical proof of concept. I’ve been working on it. Their impressive work has allowed Mirror to now move into a registered clinical trial and then into the commercial phase. All supported by such a dedicated and proven cross-functional technology team member, a talented executive management team led by an extraordinary CEO, and committed investors with a shared vision to accelerate development. We are honored to work with an experienced and skilled Board of Directors. Accessible and affordable immunotherapy for patients worldwide. “
Mr. Shen holds an MBA from Columbia Business School and an MS in Analytical Chemistry from Brigham Young University under Professor Milton L. Lee.
About Mirror Biologics, Inc.:
Mirror Biologics, Inc. was incorporated in the State of Delaware on November 5, 2018. We are a clinical-stage immunotherapy company that aims to develop treatments for cancer, infectious diseases and healthy aging indications using a platform technology called “Mirror Effect®”. We specialize in the discovery, clinical trials and manufacturing of next-generation therapeutic and preventive immunotherapy products that incorporate living immune cells as active ingredients. We are driven by compassion for patients suffering from incurable diseases and highly toxic treatments such as chemotherapy, and we advocate for toxic, curative, or life-prolonging actions that can be made widely accessible and distributed to outpatient clinics. We are developing affordable alternative treatment options. and community oncology offices worldwide.
Our therapeutic vaccine programs are designed to induce immune responses customized to a patient’s type of resident cancer or infectious disease, regardless of disease type or cancer or pathogen gene expression ( “disease-independent”). Our flagship product is a “commercial”, non-genetically engineered live immune cell called “AlloStim®” derived from healthy donor blood. AlloStim® is designed to modulate the immune system using a platform technology called the “Mirror Effect®”.
Headquartered in Tampa, Florida, it operates a blood and tissue donor center, a drug depot distribution center, a clinical research center supporting immunology and molecular biology laboratories, and is involved in the development of large-scale “artificial lymph nodes.” We are conducting bioengineering research to Bioreactor for commercial production of living immune cells. It also operates a wholly-owned subsidiary, Mirror Biologics, Ltd. (an Israeli company) in Jerusalem, which complies with Good Manufacturing Practices (“GMP”) for production aseptic cell processing, formulation and freezing. Save operation is in progress. Live AlloStim® immune cells for use in clinical trials. It also operates drug storage, blood processing and clinical site management operations through its wholly-owned subsidiary Mirror Biologics (Malaysia), Sdn Bhd in Kuala Lumpur, Malaysia, and operates these same services through its consultancy, Immunovative (Thailand) Co. make a deal. ., Ltd. (Bangkok, Thailand) Currently focused on advancing two late-stage clinical programs towards the Biological License Application (BLA) milestone. (2) Targeting advanced liver cancer in Southeast Asia. It is also conducting Phase I/II clinical trials in the United States evaluating its “universal antiviral immunomodulatory vaccine” technology.